HINOON stock snapshot.
Highnoon Laboratories Limited price, fundamentals, financial report trends, and one-year performance against the KSE-100.
HINOON vs. KSE-100
Latest report-period signals.
Parsed conservatively from PSX financial report PDFs. Card values are latest report-period figures, so quarterly filings show quarterly values rather than annualized totals.
Report metrics extracted
| Stock | Trailing P/E | Price / book | ROE | Net margin | Debt / equity | Market cap | Day change |
|---|---|---|---|---|---|---|---|
HINOON Highnoon Laboratories Limited | 12.65 | 3.69 | 31.28% | 15.97% | 41.03% | PKR 52.1bn | +0.86% |
| GLAXO →GlaxoSmithKline Pakistan Limited | 10.98 | 3.03 | 29.77% | 15.21% | 48.79% | PKR 110.1bn | -0.21% |
| ABOT →Abbott Laboratories (Pakistan) Limited | 11.27 | 2.67 | 25.19% | 10.57% | 48.93% | PKR 89.8bn | +0.36% |
| HALEON →Haleon Pakistan Limited | 13.82 | 6.05 | 43.07% | 14.78% | 105.49% | PKR 88.1bn | -0.15% |
| AGP →AGP Limited | 22.65 | 3.97 | 18.27% | 11.49% | 62.09% | PKR 53.5bn | -0.20% |
Highnoon Laboratories Limited
Highnoon Laboratories Limited (“the Company”) was incorporated in Pakistan under the repealed Companies Ordinance 1984 (now Companies Act, 2017) (“the Act”) and its shares are quoted on Pakistan Stock Exchange since November 1994. The Company is principally engaged in the manufacture, import, sale and marketing of pharmaceutical and related consumer products.
Turn HINOON from a quote into a decision trail.
PSX Clarity connects live prices, filings, dividends, and report metrics to the portfolio you actually follow.